Exact Sciences surges after marketing deal with Pfizer for cancer test
Exact Sciences Corp's shares shot up as much as 26 percent on Wednesday after the company said Pfizer Inc would share marketing expenses and co-promote the company's stool screening test for colorectal cancer. The companies will invest a combined $48 million, shared equally, next year to market the non-invasive DNA screening test Cologuard, Exact Sciences Chief Executive Officer Kevin Conroy told Reuters in an interview.
from Biotech News
0 Comments